Viamet, which has raised about $170m from backers including Novartis, Eli Lilly and Astellas, is set to raise up to $91m, after withdrawing its last IPO filing in 2014.
Viamet Pharmaceuticals, a US-based biopharmaceutical company backed by pharmaceutical firms Novartis, Astellas and Eli Lilly, yesterday set terms for an initial public offering that could raise up to $91.2m.
The company plans to issue 5.7 million shares on Nasdaq priced between $14 and $16. If underwriters Morgan Stanley, Goldman Sachs, Guggenheim Securities and Needham & Company take up the option to buy another 855,000 shares, the size of the IPO could reach almost $105m.
Founded in 2011, Viamet is…
